What Is Emphysema?

Emphysema is a pulmonary disease defined anatomically as permanent enlargement of the air spaces distal to the terminal bronchioles, accompanied by destruction of the alveolar walls and without obvious fibrosis. The definition is structural rather than symptomatic, which distinguishes emphysema from chronic bronchitis even though the two commonly coexist under the clinical heading of chronic obstructive pulmonary disease. Destroying alveolar walls removes both gas exchange surface and the elastic tissue that tethers small airways open, so the lung loses recoil, airways collapse during exhalation, and air becomes trapped. The functional signature is expiratory flow limitation with hyperinflation and a reduced diffusing capacity for carbon monoxide, with the accompanying airflow obstruction conventionally defined by a post-bronchodilator ratio of forced expiratory volume in one second to forced vital capacity below 0.70.

Cigarette smoking accounts for most cases in high-income countries, with biomass smoke exposure, occupational dusts, and ambient particulate pollution contributing substantially elsewhere. Emphysema is irreversible: no treatment restores destroyed alveolar tissue, so management targets symptom control, exacerbation prevention, and slowing further loss.

Pathogenesis

The dominant mechanistic account is an imbalance between proteases released during inflammation and the antiproteases that normally restrain them. Neutrophil elastase and proteinase 3, recruited by inhaled irritants, degrade elastin in the alveolar wall when inhibition is insufficient. The genetic proof of that model is alpha-1 antitrypsin deficiency, in which circulating inhibitor falls below a protective threshold of roughly 11 micromolar and severe early emphysema follows. A review of the molecular and cellular mechanisms in alpha-1 antitrypsin deficiency traces how the field has extended beyond that framework to include oxidative stress, apoptosis of alveolar epithelial and endothelial cells, impaired repair, and adaptive immune activation against fragments of degraded matrix.

Anatomic Patterns

Emphysema is classified by which part of the acinus is destroyed, and the pattern carries etiologic information. Centrilobular emphysema damages the respiratory bronchioles at the center of the acinus first, predominates in the upper lobes, and is the pattern typical of smoking. Panlobular emphysema destroys the acinus uniformly from respiratory bronchiole to distal alveoli, favors the lower lobes, and is characteristic of alpha-1 antitrypsin deficiency. Paraseptal emphysema sits at the periphery adjacent to pleura and interlobular septa, where coalescing spaces can form bullae and predispose to spontaneous pneumothorax. Distribution matters clinically because lung volume reduction procedures depend on finding a target lobe that is more destroyed than the rest.

Imaging and Quantification

Computed tomography has become the reference method for assessing emphysema in living patients, because destroyed parenchyma is measurably less dense than normal lung. Normal inspiratory lung attenuates at roughly -850 Hounsfield units while air approaches -1000, so thresholding the histogram isolates emphysematous voxels. The conventional density mask reports the percentage of lung below -950 Hounsfield units, with a percentile-based alternative that is less sensitive to scanner and reconstruction settings. Reviews of quantitative computed tomography in chronic obstructive pulmonary disease set out how these indices correlate with spirometry, diffusing capacity, and mortality, and where they break down. Automated methods now segment the airway tree alongside the parenchyma, and an account of the landmark work on automatic quantification of emphysema and airway disease describes how image analysis moved from visual scoring to reproducible computation. Large cohort studies have since applied machine learning to harmonize measurements across scanners and protocols.

Applications

Emphysema research and care draw on a range of technical fields, including:

• Pulmonary function testing instrumentation and body plethysmography
• Quantitative medical imaging and computer-aided diagnosis
• Thoracic surgery, including lung volume reduction and transplantation
• Bronchoscopic devices such as endobronchial valves and coils
• Respiratory support equipment, including oxygen concentrators and noninvasive ventilation
• Occupational and environmental exposure monitoring
• Medical genetics and augmentation therapy for inherited deficiency